NORFLEX
Pronunciation: or-FEN-a-dreen


What it isAntimuscarinic, H1, and NMDA antagonist used for acute musculoskeletal spasm.
Why this oneUnlike purely sedating relaxants, it adds an NMDA-linked analgesic component, though efficacy evidence is weak.
What limits itAnticholinergic burden makes it poor for older adults. Overdose can be lethal through arrhythmia, seizure, and coma.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Adjunct for acute painful musculoskeletal conditions | Adults | 1 tablet BID (one AM, one PM) | 1 tablet BID | 1 tablet BID |
Renal Undefined
Hepatic Undefined
Available strengths
Pregnancy Pregnancy Category C; use only if clearly needed
Lactation Undefined
| Strength | #/mo | generic $ | CostPlus | |
|---|---|---|---|---|
| 100 mg | ER tab | 60 BID | $27.22/mo | offered |
| 30 mg/mL | inj | per unit | $5.73/mL | not offered |
Generic entry1982
NO BOXED WARNINGS
Principal riskAnticholinergic burden; lethal in overdose
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Open Orphenadrine in the interactive console ↗
